Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Q34217642)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 19, 2011

Language	Label	Description	Also known as
English	Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer	scientific article published on September 19, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (English)

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

Michael A. Carducci

9

object named as

Michael A Carducci

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jeffrey Gingrich

4

object named as

Jeffrey R. Gingrich

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21931019

12 December 2024

author name string

Roberto Pili

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Michael Häggman

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Anders Björk

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Orjan Nordle

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Goran Forsberg

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Walter M. Stadler

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21931019

12 December 2024

Vasileios J. Assikis

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21931019

12 December 2024

Andrew J. Armstrong

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21931019

12 December 2024

language of work or name

0 references

publication date

19 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

full work available at URL

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2011.35.6295

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

4022-4028

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

3

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

4

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

5

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

6

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

7

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

8

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

9

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

The role of myeloid cells in the promotion of tumour angiogenesis

10

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

11

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

12

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

13

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

14

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

15

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

16

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

17

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

18

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

19

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

20

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies

21

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

22

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

23

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

24

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

25

1 reference

10.1200/JCO.2011.35.6295

https://api.crossref.org/works/10.1200/JCO.2011.35.6295

12 December 2024

Identifiers

10.1200/JCO.2011.35.6295

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34217642&oldid=2286509772"